News

Cracking cancer’s code through functional connections

Anna Crysler
July 2, 2025

Among cancer researchers, their computers, servers and databanks store thousands of terabytes of omics data, enabling novel discoveries about genetic and proteomic relationships. However, making meaningful connections can be computationally challenging. What if there were a way to harness the power of machine learning to help interpret this data and identify unrecognized patterns that advance therapeutic strategies?

A recent paper in Nature Cancer introduces a new tool for decoding and uncovering functional connections within cancer biology. FunMap, a machine-learning-driven platform, allows researchers to understand how genes and proteins work together in cancer, even when they aren’t directly connected. Bing Zhang, a professor of molecular and human genetics at Baylor College of Medicine, and his lab aim to bridge the gap between large-scale cancer omics data and functional interpretation using machine learning.

The team used large-scale proteogenomic data, or integrated information about genes, RNA and proteins, across 11 cancer types to chart a functional network of more than 10,000 genes. Unlike traditional protein–protein interaction networks, which focus on physical contacts between proteins, FunMap assesses “cofunctionality,” the concept that genes or proteins can participate in the same biological process even if they do not physically interact.

“Think of a complex research lab,” Zhiao Shi, lead programmer in the lab and first author of the paper, explained the computational tool. “A computational biologist and a wet lab scientist may never perform experiments together, but the computational analysis is crucial for guiding the wet lab experiments and interpreting results. Though they do not interact directly, their roles are tightly coordinated to achieve scientific breakthroughs — this is cofunction.”

With the ability to incorporate graph-neural-network-based deep learning, a type of model that learns from data structured as networks of connected elements, FunMap can identify cancer driver mutations with low frequencies. This expands the understanding of cancer pathogenesis beyond high-frequency mutations and may potentiate new discoveries in cancer diagnostics and treatment.

FunMap also advances functional genomics by shedding light on understudied cancer genes, such as RBM34 and MAB21L4, also known as dark genes. These understudied genes and their protein counterparts have not been studied in the context of cancer but are significantly over or under expressed in tumors. Shi explained that their approach “enables a more systematic and data-driven assignment of functions to poorly characterized cancer-associated genes, aiding in the discovery of novel cancer biology.”

The platform is available to the public at funmap.linkedomics.org, where scientists can explore the network and apply it to their own studies. The Zhang lab plans to expand its tool with additional data types, such as epigenomics and protein modification.

“By identifying key cancer-associated proteins and functional pathways, our findings can help prioritize therapeutic targets, ultimately contributing to the development of more effective treatments,” Shi said. “In the long run, this research could lead to improved cancer diagnostics and therapies, benefiting patients by making precision medicine more actionable and impactful.”

Overview of FunMap, a machine learning and network-based framework that integrates pan-cancer proteogenomic data to identify functional modules, predict understudied protein functions, and discover low-frequency cancer drivers.
Bing Zhang, Baylor College of Medicine
Overview of FunMap, a machine learning and network-based framework that integrates pan-cancer proteogenomic data to identify functional modules, predict understudied protein functions, and discover low-frequency cancer drivers.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Anna Crysler

Anna Crysler holds a B.A. in biochemistry from Albion College and is a is a Ph.D. student in bioengineering at the University of Pennsylvania. She is an ASBMB Today volunteer contributor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Unraveling the language of histones
Profile

Unraveling the language of histones

Nov. 20, 2025

Philip Cole presented his research on how posttranslational modifications to histones are involved in gene expression and how these modifications could be therapeutically targeted to treat diseases like cancer.

How Alixorexton could transform narcolepsy treatment
News

How Alixorexton could transform narcolepsy treatment

Nov. 18, 2025

A new investigational drug, alixorexton, targets the brain’s orexin system to restore wakefulness in people with narcolepsy type 1. Alkermes chemist Brian Raymer shares how molecular modeling turned a lab idea into a promising phase 3 therapy.

Phosphatases and pupils: A dual legacy
Profile

Phosphatases and pupils: A dual legacy

Nov. 13, 2025

Yale professor Anton Bennett explores how protein tyrosine phosphatases shape disease, while building a legacy of mentorship that expands opportunity and fuels discovery in biochemistry and molecular biology.

Extracellular vesicles offer clues to cattle reproduction
Journal News

Extracellular vesicles offer clues to cattle reproduction

Nov. 11, 2025

Extracellular vesicles from pregnant cattle support embryo development better than laboratory models, highlighting their potential to improve reproductive efficiency in bovine embryo cultures. Read more about this recent MCP paper.

Proteomics reveals protein shifts in diabetic eye disease
Journal News

Proteomics reveals protein shifts in diabetic eye disease

Nov. 11, 2025

Using proteomics, researchers identified protein changes in eye fluid that mark diabetic retinopathy progression and may serve as biomarkers for vision-threatening complications. Read more about this recent MCP paper.

Protein modifications drive lung cancer resistance
Journal News

Protein modifications drive lung cancer resistance

Nov. 6, 2025

New assay enriches protein modifications in a single process, enabling detection of key changes in drug-resistant lung cancer cells that may guide future therapies.